Safety and Efficacy of Secukinumab in Mild Psoriasis
Status:
Completed
Trial end date:
2021-06-21
Target enrollment:
Participant gender:
Summary
Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic
inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing
mild psoriasis with a short-term anti- interleukin (IL)-17A treatment, investigators may
reduce the costs of treating psoriasis and associated medical conditions, including psoriatic
arthritis, cardiovascular disease, and diabetes.